RxSight, Inc. (RXST) Earnings Call Transcript
May 6, 2026
Earnings Call Speaker Segments
Thanks, operator. Joining us today are RxSight's President and Chief Executive Officer, Dr. Ron Kurtz, along with our Chief Financial Officer, Mark Wilterding. RxSight put out its financial results earlier today for the 3 months that ended March 31, 2026. You can find a copy of that press release on the company's website. Before we get started, I want to remind everyone that what we say and how we answer questions on this call today reflects management's views as of today, and it will include forward-looking and opinion statements — predictions, estimates, plans and expectations among them. Actual results may differ materially from what's expressed or implied because of certain risks and uncertainties. You can find a fuller description of those risks and uncertainties in the press release we put out today, as well as in the documents we file with the Securities and Exchange Commission, or SEC. Those filings are available on our website and on the SEC's site. We remind investors not to rely too heavily on forward-looking statements, and we take no responsibility for updating or revising them unless the law requires it. In addition, we'll be talking about some non-GAAP financial measures. The press release contains the relevant disclosures about those non-GAAP measures, including reconciliations to the closest comparable GAAP measures. Also, keep in mind that an audio replay of this call will be posted on our Investor Relations website. Having said that, I'll now hand things over to Ron. Ron?
Good afternoon, everyone, and thanks for being with us today. Before Mark walks us through the Q1 numbers, I want to give you an overview of how our commercial efforts are progressing, beginning with the Annual Meeting of the American Society of Cataract and Refractive Surgery, which took place just a few weeks ago in Washington, D.C. That gathering is the biggest U.S. meeting centered on refractive and premium cataract surgery, and RxSight's light adjustable lens technology remained a major point of interest for physicians. More than 30 papers and posters were presented, and many podium discussions underscored the consistency, precision and versatility the LAL delivers for cataract surgeons and their patients. At that meeting, we also celebrated a significant milestone: 300,000 LAL implants since commercialization in the U.S. We also introduced our I Trust It With My Own Eyes campaign, which features ophthalmologists who selected the Light Adjustable Lens for their own eyes. These physician-as-patient stories confirm what our survey data already tells us. Close to 80% of ophthalmologists and optometrists indicate they would pick the LAL for themselves or someone they love, which shows how much confidence doctors place in the LAL's capacity to provide high-quality, customized binocular vision. Our experience at ASCRS lines up with what we see happening in everyday clinical settings. To put it more precisely: when physicians witness firsthand how dependable postoperative adjustability is for achieving these kinds of results, their confidence grows, and that translates into the high-value revenue that is so critical to a practice's overall health, especially given the reimbursement squeeze we've seen lately. When the year began, a major item on our team's agenda was continuing to hone the customer reengagement initiatives introduced during the latter half of 2025, while accelerating that work throughout 2026 and afterward. There's still more to do, yet we take encouragement from how far we've come during this year. When it comes to LAL, our volumes were in line with what we saw a year ago, and utilization has leveled off now for a third quarter in a row. Perhaps more significantly, we're starting to pick up on unmistakable signs that the work we've been doing is delivering results — particularly within practices where we've gotten physicians and staff involved again through clinical outcome reviews, targeted IOL counseling training, refresher education and in-person workflow support. Turning to our international business, we're staying the course with a disciplined, deliberate strategy for expansion, with the goal of creating a lasting base for long-term growth beyond the U.S. What we're concentrating on is putting the right clinical, commercial and operational infrastructure in place in every market, and on building ties with top surgeons who can help drive adoption as time goes on. In line with those efforts, we were glad to secure approval in New Zealand during the past month, representing one more move toward broadening the LAL system's footprint worldwide. Although we anticipate that overseas contributions will remain limited for now, the potential beyond the United States is substantial and should emerge as a more significant growth engine starting in 2027 and continuing afterward. On that note, I'll hand things over to Mark, who will walk us through the first quarter's financial results as well as our guidance for the rest of the year.
Thanks, Ron. Our first-quarter revenue was $30.9 million, a decline of 18%, reflecting the anticipated year-over-year drop in LDD unit volumes. During the quarter, we sold 20 LDDs, which accounted for approximately $2 million in sales. We ended the quarter with an installed base of 1,154 LDD units. LAL unit volumes for Q1 totaled 27,472, consistent with the prior-year period and down 4% sequentially. That sequential decline was in line with normal first-quarter seasonality. LAL procedure volumes generated roughly $27 million in Q1 sales, representing 88% of total company sales in the first quarter. Our gross margin reached 76.1% thanks to a larger share of LAL revenue, up from 74.8% during the same period last year. SG&A for the first quarter of 2026 came in at $31.9 million, an 11% increase over the prior year period, which reflects personnel-related costs as we continue to prioritize hiring investments and the expansion of our commercial and support teams worldwide. Research & Development spending for the first quarter was $9.5 million, a 9% decline compared with a year ago. For the first quarter, we posted a net loss of $15.9 million, equal to $0.38 per basic and diluted share, with 41.3 million weighted average shares outstanding. Stock-based compensation totaled $7.9 million, bringing adjusted net loss to $7.9 million, or $0.19 per share. Now for our outlook on 2026. Our projection for the full year's revenue stays at $120 million to $135 million. As we mentioned back in February, we expect the pace of quarterly sales increases to pick up as the year goes on, since we're assuming better underlying conditions and easier comparisons against last year. Like Ron said, we see our overseas operations adding a small amount to 2026 sales, mostly from initial capital installations. We'll keep growing beyond the U.S. in a careful, step-by-step manner to set the company up for lasting growth over the long term. Our gross margin target for 2026, 70% to 72%, is also still the same. We've already told you that the drop we expect in Q1 gross margin comes from carrying through inventory made in 2025 that cost us more. As time goes on, we think manufacturing absorption will get better once production settles into more normal levels. Our forecast for 2026 operating expenses puts them at the top of the $150 million to $160 million range we gave before, which mirrors stepped-up spending on our global commercial organization. When it comes to phasing, we see quarterly operating expenses tracking a pattern much like 2025, with heavier spending during the first half. Within our costs, mostly in operating expenses, our expectation for noncash stock-based compensation remains $30 million to $32 million. Having said that, I'll now hand things back over to Ron.
Thanks, Mark. To sum up, the fundamental clinical value that LAL provides is still robust and plainly distinct within the premium IOL sector, since it lets surgeons tailor vision post-operatively, which yields better results for patients and strong financial advantages for practices. Even though many Me-Too Fixed IOLs have entered the market, our belief is unchanged that adjustability is the next significant advance. Looking at our current position, the business seems to be steadying, and our customer engagement initiatives are starting to demonstrate early momentum, which gives us the assurance to keep honing the model and grow it worldwide at a careful pace. Simultaneously, we're concentrating on bolstering our team, sharpening execution, and pursuing technical breakthroughs that make implementation even simpler while producing top-tier outcomes; we're eager to provide more information about these forthcoming commercial launches, which should lower adoption hurdles for clinicians and patients alike by making the clinical workup for post-op adjustments more efficient, cutting down on how many LDD treatments are needed, and broadening the scope of correction. With that said, I'll turn it over to the operator to begin the Q&A.
It was encouraging to see you gain some traction and turn in a slight beat versus what the Street expected. Could you perhaps walk us through what conditions look like out in the market, and how certain pieces of this turnaround effort are landing, what the response has been like? And do you detect any early signs of further gains as we head into Q2? Then I've got one quick follow-up.
Sure. Thanks, Robbie. Without saying anything about Q2, which we're clearly sitting in right now, I'd tell you the response we're hearing from customers — and equally important, from our own people — has been quite favorable as we keep launching reengagement initiatives, like the ones I outlined, tied to a handful of highly targeted moves through which we can examine clinical outcomes along with the insights collected during the last several years while this technology got deployed throughout the U.S. And at this point we feel confident that ongoing fine-tuning and broadening of those initiatives can drive additional improvement when it comes to utilization across our customer base, which, as you're aware, is very sizable.
Looking at how the year shapes up, it suggests a fairly modest step-up from one period to the next. How confident are you in your capacity to expand in 2027? And past certain adjustments, what steps are you taking to genuinely spark renewed enthusiasm for LALs, so you get back to a significant growth rate and produce profitability once more?
Robbie, this is Mark. I appreciate the question. Our stated expectation is that growth rates will strengthen as the year progresses. That stems from two things: our conviction that fundamentals are going to get better, driven by some of what Ron just described, plus comparisons becoming easier; as for expansion in 2027, we have not, as you're aware, provided guidance that far ahead. Still, we view ourselves as a growth-oriented company. We put money to work for long-term sustainable growth, and that covers 2027 and beyond. Ron, is there anything further you'd like to add there?
Yeah. I believe, the factors we've discussed involve ongoing improvements in technology, which are going to keep making it easier to put the LAL into practice, in the U.S. as well as progressively beyond the U.S., where we're beginning to build a presence. So I'd say those two things are going to drive growth. I'd add that it isn't the case that we've — I wouldn't describe what's happened with us as people losing interest in the LAL. My sense is there's still a good deal of enthusiasm for the LAL, and we witnessed that, as I brought up regarding the ASCRS meeting, where it remains a top area of curiosity among the medical community, and also at our booth, which had a great deal of traffic. So, I think what's happening is that we're channeling that enthusiasm into growth by way of the programs we've described.
I'd like to build a bit on what Robbie asked. This is a difficult one, but I'm wondering how much of the stabilization in your LAL adoption, in your view, simply reflects the cataract market staying flat — especially where AT-IOLs are concerned — rather than getting worse compared with roughly 12 months back, as opposed to the work you're doing to reverse the commercial adoption trend; and I'm not sure whether you can break that apart, but I'd love for you to give it a try.
As you pointed out in asking that, it's always difficult to break apart every one of the factors involved. From the feedback we've received so far, my belief is that the steps we're taking, with everything else held constant, are constructive and are making a difference. Naturally, it helps a great deal when the market moves your way too, and we very much hope that's what's happening. Still, with respect to what's within our control, we believe our impact is a constructive one, and we'll keep at it as these programs grow and get sharpened.
And as a quick follow-up, at this stage are you limiting LDD sales? In other words, is there demand from customers that you're deliberately not acting on when it comes to LDD sales? Or has it simply not been made a priority within the sales force right now?
I wouldn't say that's the case, I'd describe it as gating. What I'd say is we're adopting a more measured approach, because our goal is for customers to be completely ready to take on the technology and to succeed with it. That isn't to say we weren't doing so previously, but I believe the sheer newness of the LAL during those first several years simply pushed things along at a quicker rate. So at this point we've moved into something more gradual, though there's still plenty of robust interest, and we expect to keep adding LDDs, clearly OUS, and in the U.S. as well.
Perhaps I could ask one about the guidance, Mark. During the previous quarter, I believe you mentioned an expectation of low single-digit growth in LAL volumes for this year. You finished above consensus in Q1. So, is low single digits still the right lens for 2026? Or might we be trending toward mid-singles? The second half of my question: how far does that take us in working through the higher cost inventory? For instance, at low single digits, does that clear everything sitting on the balance sheet?
Yes. Appreciate the question. As I said, it came in somewhat ahead of what we expected, yet not enough that we thought raising guidance was justified; therefore, I believe your assumption, grounded in what we shared in February, remains correct regarding LAL growth sitting in that low single-digit band across the full year. Once more, we anticipate quarterly growth rates picking up sequentially throughout the year, as I noted previously. That said, at this stage, in year 2, it's always difficult given how early we are to project any further out. So taking a more cautious stance seems wise, and that's the approach we've taken with the LAL guidance. On the inventory side, our assumptions are unchanged as well. You can see this mostly reflected in the gross margin guidance we provided; we still expect to end the year within that 70% to 72% range. Q1, as anticipated and as we communicated in February, wasn't really affected by those absorption issues, though we do expect them to appear in Q2 and throughout the rest of this year. And we're watching it carefully. We haven't specified when that will ease or what it might look like next year; but once we're nearer to a point where we can offer longer-term guidance, we'll provide an update on that too.
Then for my second question, it's about the commercial pivot, or the reengagement strategy. I'd really like to know what share of accounts or territories you've actually rolled that out in. And after you've done so and secured the account's buy-in, how should we think about the utilization that results over the following months or quarters?
Yeah. I'd say we're still in the early innings when it comes to getting through the installed base, which, as you're aware, is pretty sizable — roughly 1,150 LDDs, 2,500 surgeons. So that's going to keep going all year and on into '27. As for what results we're seeing and what you'd expect, naturally it'll show up in the figures you'll see, and it'll be more gradual, since it has to stretch across the installed base. On an individual level, though, we're definitely seeing the effect, and we feel that as we keep refining the programs and the way we roll them out, that's going to keep accelerating.
Ron, I've got a question about the U.S. market and one about outside the country. So what's your take on the way competition is heating up in premium IOLs? We're aware that several additional ones are launching during this year. From J&J, clearly, you've got TECNIS PureSee. A BVI offering exists. Rayner, as I understand it, is about to enter. How did you factor all of that into the guidance, in your view? And I had something else to ask after that.
That's a fair question, Larry. Basically, my view is that when it comes to these launches of new products, there isn't much that's genuinely novel. Naturally, when you have several companies competing in the market, even when their products aren't differentiated, the result is still a greater number of voices being heard. So we're keeping an eye on it, yet our conviction is strong that the clinical results you can achieve through adjustability are better and in the end will prevail, even though, just as happened with launches in the past, there may be some short-lived effects from these moves and from how they affect other rivals generally.
Then on the international side, I'd really like to hear how things are going with your efforts abroad. Which places are beginning to show some early traction, so to speak? And that phrase "modest contribution" — I believe I caught it earlier during this call, referring to '26. Does that mean something like $5 million or $10 million?
The dollar amount, I'll leave for Mark to address. As for where, we've already told you the locations where approvals came through. Clearly, that comes first — ahead of commercial launch and any traction. The latest approvals, and the places we've managed to get underway, have mostly been in Asia, with Korea plus smaller markets such as Singapore, though it's a significant market. More recently we secured approval in Europe. Those initiatives are now getting going too, starting to build traction, particularly around awareness in the bigger European countries. And most recently, Australia and now New Zealand. I'd say those nations largely reflect where the premium IOL business has seen its greatest success. We frequently observe that new product launches trace a quite similar path of rollout in places such as the major European countries, Korea, Australia, and so on. Naturally, the nations with longer regulatory timelines that remain significant — Japan, China and India — those are the ones we're still working through.
Regarding putting a number on that, Larry, I realize you've raised this before. The group is putting in effort and pushing hard on it. We have a strong team assembled, though when it comes to dollar figures, we don't yet consider it significant enough to report separately. Once that shifts—and it will, eventually—we'll make certain to bring you up to date.
A rival just put out results not long ago and pointed to weakness in the cataract sector. So I'm wondering whether that's something you're observing across the whole market, though perhaps you feel less of a hit because of your premium product. So yeah, I'd just like to hear your perspective on that.
Well, the scale of that rival compared with us, I believe, provides them with substantial insight into the market as a whole. And yet, my sense is that what they said applied more to the non-premium part of the market, the conventional cataract procedure portion, and they likewise mentioned ongoing expansion in the premium segment, in the U.S. as well as abroad. And those things would align with our long-term perspective too, given the clinical and economic advantages of premium IOL technology in general and, more specifically, the LAL. So nothing we're observing strikes me as inconsistent. We also experienced some weakness across the cataract market 12 months ago. And back then, I believe certain people wondered whether those were more driven by macro factors, since patients within that subgroup still must cover co-pays, which can be fairly costly depending on the demographic. And so that segment could be getting affected first.
Understood. Then I’d like to ask a follow-up about the OpEx guidance, which is now leaning toward the upper portion of that band. What I’m wondering is which investment areas are mainly going up? And how should we think about OpEx and the timing for it to help revenue?
I’d basically restate part of what Ron said before about the OpEx guidance: we’re highly focused on delivering, as I’d put it, the strongest levels of clinical training and field support, in the U.S. as well as internationally. That calls for spending to back new and current customers, with a key emphasis on driving penetration in those accounts. Because of that, we’re clearly concentrating on putting additional resources into areas like those, plus customer support, education, sales and marketing, and continuing to move our R&D pipeline forward—something we’ve funded for quite a while and aren’t slowing down on either. So those, I’d say, are the main investment channels you’re seeing as that OpEx pattern shifts toward the upper portion of the range.
Kyle Winborne here, filling in for Adam. So, to pick up where we left off on OpEx, perhaps this is a good moment for you to walk us through where the company stands right now in terms of commercial head count? From what I'm hearing, the intention may be to keep bringing on more people, if I've got that right. So while these efforts are ongoing, should we essentially expect OpEx to keep running at this rate for the foreseeable future? I also had a follow-up question.
Yes. We've got roughly 130 to 150 employees who are field-facing; that figure has kept increasing alongside our installed base, and also with the newer initiatives we've discussed. And of course, when it comes to where we put the extra spending, we'll be making calls based on how well those initiatives perform and on other business priorities, though that's a decision we're always managing on an ongoing basis.
That's useful detail. Now for my follow-up — you brought up innovation a bit and provided some useful context regarding upcoming items. I was just curious whether you might go deeper on any of them, anything that stands out as especially significant. You also noted that we could learn about a few of these at some point later in this year. So it seems like we ought to view this as having more of an effect as we move toward 2027.
Yeah, I'd say everything I listed is something that has long been regarded as an advantage for the technology's progress within the spaces we've been focused on. Those initiatives require time. We're dealing with a Class III device. That means we must complete the PMA supplement process, and that's what we're doing. Still, once we can see a path to commercialization, we'll definitely pass that along and provide visibility to the investor community as well as to our customers.
So for the first thing, regarding those programs aimed at bringing customers back. I was curious whether you might tell us a little more about what the practice side of that looks like. You mentioned a handful of instances, yet which of those lands best with the surgeons and the people working alongside them? Plus, which main problems do practices require your assistance to resolve?
Honestly, it varies, naturally, from one practice to the next. That is precisely why our group matters so much when it comes to evaluating and talking through with each practice which actions are most apt to drive better outcomes for them, benefiting them on the clinical side as well as the financial side. It therefore must be seen as something both sides gain from, and that, in my view, is how our customer base perceives and values it — that we keep putting resources into helping them win. Among the particular actions I brought up, a few involve our distinctive capacity to monitor clinical outcomes for practically every single patient; yet that data can end up trapped in separate parts of the practice. Consequently, spelling it out for the whole practice — the optometrists who could be performing the LDD treatment, the ophthalmologists who might not be checking on that postoperative patient as often, plus the staff who might not know the finer points, the clinical staff and the surgery counselors — simply making that data accessible to more people, something only we can accomplish, is incredibly encouraging, since it shows how much adjustability changes the lives of their patients; they witness that informally, yet seeing it in measurable terms, which, once more, no other IOL can truly achieve absent a clinical study, which generally isn't feasible. The remaining efforts on our part genuinely vary by practice. For instance, they might be workflow tips drawn from comparable practices — perhaps alike in size, alike in composition, alike in socioeconomic makeup — and how those practices handle patient flow, the postoperative visits, how tasks get divided, how expectations get established and managed across the whole journey; all of these are clinical and practice capabilities that were absent 5 years ago; and we alongside our customers have worked out a great deal of it. And at this point we must return and spread that knowledge through different channels, be it our own direct dealings with practices, be it practice-to-practice exchanges, or be it digital media. Each of those represents a method by which we connect with our customers.
Okay, sounds good. That's really useful. Then I suppose I have one more thing — I was hoping to get a bit of color on those customers who purchased LDDs over the last 12 months or the last 3 quarters, the ones sitting at 20 to 25 LDDs, as opposed to earlier stretches when roughly 70-plus were being bought each quarter. Since there are fewer of them now, presumably these are more focused or more driven purchasers, I'm just wondering whether you're noticing any shifts in how they utilize the product or how their adoption curve looks compared with earlier periods or cohorts?
That's a fair question. My sense is it may be a bit soon to tell — as you mentioned, we're talking about the smaller end of things; so we'll keep monitoring that. That said, naturally we're folding in everything we're doing around the reengage practices into our onboarding efforts too. So with any luck, we'll end up seeing those same advantages show up in that segment as their onboarding moves along.
Sorry if this was already covered — I'm bouncing between several calls. I'd like to begin with the competitive environment, though focusing more narrowly on adjustable. Ron, what are you currently hearing regarding competition in adjustable? Is there anything new we ought to know about? Also, I'm interested whether you could say something about Perfect Lens, which as I understand is growing its presence in Europe. Then I'll come back with another question.
There isn't anything particular I can share. Naturally, we keep watching this area. To the best of my awareness, nothing is nearing a regulatory submission, and definitely not within the U.S. Everyone understands how demanding the requirements are, and we have kept pushing those requirements higher. Beyond that, naturally, we possess a sizable installed base and a great deal of understanding has accumulated among the community around our technology; so I don't mean to sound as though competition doesn't matter. I simply also believe folks ought to keep a realistic view of just how long any possible rival offering might take to arrive.
Understood, that's excellent. So perhaps shifting gears somewhat toward what I'd describe as the longer horizon. When you consider utilization trends, interest in adoption, and how reengagement is progressing in the U.S., Ron, could you discuss how confident you feel right now that LAL is a niche within the U.S., and even more crucially, whether it can sustainably outpace the market over time and keep capturing share in the long run?
Yeah. Well, I believe we mentioned this earlier—I'm not sure whether you were on the call, Tom—but someone brought up a major competitor that also reported today, and naturally we tuned into that call too. I found it informative because they highlighted once more, as they have previously, how critically important the premium market is to ophthalmology. The amount of attention devoted to the premium market was striking, despite the fact that it represents a comparatively minor share of their business. They also forecast that in their estimation, that premium market will expand from today's 15% to 20%, varying by geography, up to perhaps 30% to 40%. I suspect that's likely correct—they seem to have a solid grasp of it. Yet the question becomes: where will that expansion originate? Multifocal technology and standard toric technology have existed for 20 years. It has to originate from someplace, and in my view, the LAL stands apart because it can be applied broadly across patients since it maintains quality of vision. It's highly adaptable and intuitively resonates with the coming generation of patients, who not only wish to preserve their function across numerous conditions, but also desire control and a voice in the process. All of those factors, I believe, suit the LAL well and will assist the field in driving growth toward that larger figure.
Alright, we appreciate everyone taking an interest in RxSight, and we're definitely eager to bring you updates on how things are going in upcoming quarters. Farewell, and have a good evening.
This concludes today's call. Thank you for attending. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete RxSight, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to RxSight, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.